BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feng F, Jiang Q, Cao S, Cao Y, Li R, Shen L, Zhu H, Wang T, Sun L, Liang E, Sun H, Chai Y, Li X, Liu G, Yang R, Yang Z, Yang Y, Xin S, Li BA. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma. Biochim Biophys Acta Gen Subj 2018;1862:1017-30. [PMID: 29369785 DOI: 10.1016/j.bbagen.2018.01.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 69] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Kamaraj R, Drastik M, Maixnerova J, Pavek P. Allosteric Antagonism of the Pregnane X Receptor (PXR): Current-State-of-the-Art and Prediction of Novel Allosteric Sites. Cells 2022;11:2974. [DOI: 10.3390/cells11192974] [Reference Citation Analysis]
2 Wang H, Chu F, Zhijie L, Bi Q, Lixin L, Zhuang Y, Xiaofeng Z, Niu X, Zhang D, Xi H, Li B. MTBP enhances the activation of transcription factor ETS-1 and promotes the proliferation of hepatocellular carcinoma cells. Front Oncol 2022;12:985082. [DOI: 10.3389/fonc.2022.985082] [Reference Citation Analysis]
3 Mao D, Xu M, Jiang Q, Sun H, Sun F, Yang R, Chai Y, Li X, Li B, Li Y. A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma. Front Pharmacol 2022;13:951831. [DOI: 10.3389/fphar.2022.951831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Du F, Sun H, Sun F, Yang S, Tan H, Li X, Chai Y, Jiang Q, Han D. Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs. Front Pharmacol 2022;13:924523. [DOI: 10.3389/fphar.2022.924523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ma DB, Liu XY, Jia H, Zhang Y, Jiang Q, Sun H, Li X, Sun F, Chai Y, Feng F, Liu L. A Novel Small-Molecule Inhibitor of SREBP-1 Based on Natural Product Monomers Upregulates the Sensitivity of Lung Squamous Cell Carcinoma Cells to Antitumor Drugs. Front Pharmacol 2022;13:895744. [PMID: 35662712 DOI: 10.3389/fphar.2022.895744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Mustonen E, Pantsar T, Rashidian A, Reiner J, Schwab M, Laufer S, Burk O. Target Hopping from Protein Kinases to PXR: Identification of Small-Molecule Protein Kinase Inhibitors as Selective Modulators of Pregnane X Receptor from TüKIC Library. Cells 2022;11:1299. [DOI: 10.3390/cells11081299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Liu YY, Ding CZ, Chen JL, Wang ZS, Yang B, Wu XM. A Novel Small Molecular Inhibitor of DNMT1 Enhances the Antitumor Effect of Radiofrequency Ablation in Lung Squamous Cell Carcinoma Cells. Front Pharmacol 2022;13:863339. [PMID: 35401185 DOI: 10.3389/fphar.2022.863339] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Sun B, Long Y, Xiao L, Wang J, Yi Q, Tong D, Li K, Wu G. Target Protein for Xklp2 Functions as Coactivator of Androgen Receptor and Promotes the Proliferation of Prostate Carcinoma Cells. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/6085948] [Reference Citation Analysis]
9 Wei K, Gao G, Chou Y, Lin C, Chen S, Chen Y, Choi HQ, Cheng C, Su JJ. Sorafenib is an antagonist of the aryl hydrocarbon receptor. Toxicology 2022. [DOI: 10.1016/j.tox.2022.153118] [Reference Citation Analysis]
10 Niu X, Wu T, Li G, Gu X, Tian Y, Cui H. Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance. Int J Biol Sci 2022;18:742-59. [PMID: 35002522 DOI: 10.7150/ijbs.68724] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Shen LJ, Sun HW, Chai YY, Jiang QY, Zhang J, Li WM, Xin SJ. The Disassociation of the A20/HSP90 Complex via Downregulation of HSP90 Restores the Effect of A20 Enhancing the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents. Front Oncol 2021;11:804412. [PMID: 34976842 DOI: 10.3389/fonc.2021.804412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Luo M, Sun H, Jiang Q, Chai Y, Li C, Yang B, Hong Z. Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma. Front Oncol 2021;11:777356. [PMID: 34926286 DOI: 10.3389/fonc.2021.777356] [Reference Citation Analysis]
13 Yang H, Zhang MZ, Sun HW, Chai YT, Li X, Jiang Q, Hou J. A Novel Microcrystalline BAY-876 Formulation Achieves Long-Acting Antitumor Activity Against Aerobic Glycolysis and Proliferation of Hepatocellular Carcinoma. Front Oncol 2021;11:783194. [PMID: 34869036 DOI: 10.3389/fonc.2021.783194] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
14 Liu J, Yang C, Huang XM, Lv PP, Yang YK, Zhao JN, Zhao SY, Sun WJ. Knockdown of FBI-1 Inhibits the Warburg Effect and Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeted Agents via miR-3692/HIF-1α. Front Oncol 2021;11:796839. [PMID: 34869045 DOI: 10.3389/fonc.2021.796839] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
15 Qiao EQ, Yang HJ, Yu XF, Gong LJ, Zhang XP, Chen DB. Curcuma zedoaria petroleum ether extract reverses the resistance of triple-negative breast cancer to docetaxel via pregnane X receptor. Ann Transl Med 2021;9:1389. [PMID: 34733941 DOI: 10.21037/atm-21-4199] [Reference Citation Analysis]
16 Wang J, Liu R, Zhao Y, Ma Z, Sang Z, Wen Z, Yang X, Xie H. Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging. Front Oncol 2021;11:743055. [PMID: 34513717 DOI: 10.3389/fonc.2021.743055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wang JH, Zeng Z, Sun J, Chen Y, Gao X. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients. Pharmacol Res 2021;173:105869. [PMID: 34481973 DOI: 10.1016/j.phrs.2021.105869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
18 He X, Sun H, Jiang Q, Chai Y, Li X, Wang Z, Zhu B, You S, Li B, Hao J, Xin S. Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4. Front Oncol 2021;11:735447. [PMID: 34381736 DOI: 10.3389/fonc.2021.735447] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
19 Dahiya M, Dureja H. Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms. J Chemother 2021;:1-16. [PMID: 34291704 DOI: 10.1080/1120009X.2021.1955202] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Matheux A, Gassiot M, Fromont G, Leenhardt F, Boulahtouf A, Fabbrizio E, Marchive C, Garcin A, Agherbi H, Combès E, Evrard A, Houédé N, Balaguer P, Gongora C, Mbatchi LC, Pourquier P. PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1. Cancers (Basel) 2021;13:3635. [PMID: 34298852 DOI: 10.3390/cancers13143635] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
21 Jiang Q, Ma Y, Han J, Chu J, Ma X, Shen L, Liu B, Li BA, Hou J, Bi Q. MDM2 Binding Protein Induces the Resistance of Hepatocellular Carcinoma Cells to Molecular Targeting Agents via Enhancing the Transcription Factor Activity of the Pregnane X Receptor. Front Oncol 2021;11:715193. [PMID: 34249768 DOI: 10.3389/fonc.2021.715193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zou XZ, Zhou XH, Feng YQ, Hao JF, Liang B, Jia MW. Novel inhibitor of OCT1 enhances the sensitivity of human esophageal squamous cell carcinoma cells to antitumor agents. Eur J Pharmacol 2021;907:174222. [PMID: 34087221 DOI: 10.1016/j.ejphar.2021.174222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zhou Q, Liu M, Shao T, Xie P, Zhu S, Wang W, Miao Q, Peng J, Zhang P. TPX2 Enhanced the Activation of the HGF/ETS-1 Pathway and Increased the Invasion of Endocrine-Independent Prostate Carcinoma Cells. Front Oncol 2021;11:618540. [PMID: 34123781 DOI: 10.3389/fonc.2021.618540] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
24 Du Y, Shi X, Ma W, Wen P, Yu P, Wang X, Fang P, Chen A, Gao Z, Cui K. Phthalates promote the invasion of hepatocellular carcinoma cells by enhancing the interaction between Pregnane X receptor and E26 transformation specific sequence 1. Pharmacol Res 2021;169:105648. [PMID: 33965509 DOI: 10.1016/j.phrs.2021.105648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
25 Wang Y, Liu S, Chen Q, Ren Y, Li Z, Cao S. Novel small molecular inhibitor of Pit-Oct-Unc transcription factor 1 suppresses hepatocellular carcinoma cell proliferation. Life Sci 2021;277:119521. [PMID: 33891940 DOI: 10.1016/j.lfs.2021.119521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
26 Zhang R, Huang M, Wang H, Wu S, Yao J, Ge Y, Lu Y, Hu Q. Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion. Pathol Oncol Res 2021;27:597527. [PMID: 34257549 DOI: 10.3389/pore.2021.597527] [Reference Citation Analysis]
27 Li B, Feng F, Jia H, Jiang Q, Cao S, Wei L, Zhang Y, Lu J. Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells via the miR-148a/PXR axis. Food Funct 2021;12:2404-17. [PMID: 33570057 DOI: 10.1039/d0fo02270e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
28 Burk O, Kronenberger T, Keminer O, Lee SML, Schiergens TS, Schwab M, Windshügel B. Nelfinavir and Its Active Metabolite M8 Are Partial Agonists and Competitive Antagonists of the Human Pregnane X Receptor. Mol Pharmacol 2021;99:184-96. [PMID: 33483427 DOI: 10.1124/molpharm.120.000116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhao H, Cheng X, Yu J, Li Y. Stabilization of snail maintains the sorafenib resistance of hepatocellular carcinoma cells. Arch Biochem Biophys 2021;699:108754. [PMID: 33450239 DOI: 10.1016/j.abb.2021.108754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Zhou W, Gao Y, Tong Y, Wu Q, Zhou Y, Li Y. Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma. Pharmacol Res 2021;164:105392. [PMID: 33348023 DOI: 10.1016/j.phrs.2020.105392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
31 Flannery PC, Abbott KL, Pondugula SR. Correlation of PPM1A Downregulation with CYP3A4 Repression in the Tumor Liver Tissue of Hepatocellular Carcinoma Patients. Eur J Drug Metab Pharmacokinet 2020;45:297-304. [PMID: 31792727 DOI: 10.1007/s13318-019-00595-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
32 Adenina S, Louisa M, Soetikno V, Arozal W, Wanandi SI. The Effect of Alpha Mangostin on Epithelial-Mesenchymal Transition on Human Hepatocellular Carcinoma HepG2 Cells Surviving Sorafenib via TGF-β/Smad Pathways. Adv Pharm Bull 2020;10:648-55. [PMID: 33062605 DOI: 10.34172/apb.2020.078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Yang H, Ren L, Wang Y, Bi X, Li X, Wen M, Zhang Q, Yang Y, Jia Y, Li Y, Zang A, Wei Y, Dai G. FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis. Cell Death Dis 2020;11:851. [PMID: 33051436 DOI: 10.1038/s41419-020-03053-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
34 Chauhan N, Dhasmana A, Jaggi M, Chauhan SC, Yallapu MM. miR-205: A Potential Biomedicine for Cancer Therapy. Cells 2020;9:E1957. [PMID: 32854238 DOI: 10.3390/cells9091957] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
35 Wang C, Ding S, Sun B, Shen L, Xiao L, Han Z, Huang H. Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib. Pharmacol Res 2020;161:105110. [PMID: 32755614 DOI: 10.1016/j.phrs.2020.105110] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
36 Shao QP, Wei C, Yang J, Zhang WZ. miR-3609 Decelerates the Clearance of Sorafenib in Hepatocellular Carcinoma Cells by Targeting EPAS-1 and Reducing the Activation of the Pregnane X Receptor Pathway. Onco Targets Ther 2020;13:7213-27. [PMID: 32801751 DOI: 10.2147/OTT.S246471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
37 Feng YQ, Li BA, Feng F, Chen YS, Ren YX, Zhang H, Cao S. Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents. Onco Targets Ther 2020;13:7165-76. [PMID: 32801748 DOI: 10.2147/OTT.S244474] [Cited by in Crossref: 9] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
38 Ma Y, Chai N, Jiang Q, Chang Z, Chai Y, Li X, Sun H, Hou J, Linghu E. DNA methyltransferase mediates the hypermethylation of the microRNA 34a promoter and enhances the resistance of patient-derived pancreatic cancer cells to molecular targeting agents. Pharmacol Res 2020;160:105071. [PMID: 32659427 DOI: 10.1016/j.phrs.2020.105071] [Cited by in Crossref: 12] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
39 Yu C, Wang Y, Liu T, Sha K, Song Z, Zhao M, Wang X. The microRNA miR-3174 Suppresses the Expression of ADAM15 and Inhibits the Proliferation of Patient-Derived Bladder Cancer Cells. Onco Targets Ther 2020;13:4157-68. [PMID: 32547057 DOI: 10.2147/OTT.S246710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
40 Feng YQ, Gu SX, Chen YS, Gao XD, Ren YX, Chen JC, Lu YY, Zhang H, Cao S. Virtual Screening and Optimization of Novel mTOR Inhibitors for Radiosensitization of Hepatocellular Carcinoma. Drug Des Devel Ther 2020;14:1779-98. [PMID: 32440103 DOI: 10.2147/DDDT.S249156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
41 Xie J, Lu Y, Yu B, Wu J, Liu J. Galactose-modified enzymatic synthesis of poly(amino-co-ester) micelles for co-delivery miR122 and sorafenib to inhibit hepatocellular carcinoma development. Chinese Chemical Letters 2020;31:1173-7. [DOI: 10.1016/j.cclet.2019.10.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
42 Wang S, Li T, Du J, Han M, Ju D. [Pregnane X receptor promotes programmed cell death protein 4 expression in HepG2 cells]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:370-5. [PMID: 32376574 DOI: 10.12122/j.issn.1673-4254.2020.03.14] [Reference Citation Analysis]
43 Bhagyaraj E, Ahuja N, Kumar S, Tiwari D, Gupta S, Nanduri R, Gupta P. TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR. Cell Cycle 2019;18:3589-602. [PMID: 31739702 DOI: 10.1080/15384101.2019.1693120] [Cited by in Crossref: 19] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
44 Yang B, Wang C, Xie H, Wang Y, Huang J, Rong Y, Zhang H, Kong H, Yang Y, Lu Y. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis 2019;10:784. [PMID: 31611551 DOI: 10.1038/s41419-019-2023-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
45 Sun H, Feng F, Xie H, Li X, Jiang Q, Chai Y, Wang Z, Yang R, Li R, Hou J. Quantitative examination of the inhibitory activation of molecular targeting agents in hepatocellular carcinoma patient-derived cell invasion via a novel in vivo tumor model. Animal Model Exp Med 2019;2:259-68. [PMID: 31942558 DOI: 10.1002/ame2.12085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
46 Hlady RA, Zhao X, Pan X, Yang JD, Ahmed F, Antwi SO, Giama NH, Patel T, Roberts LR, Liu C, Robertson KD. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA. Theranostics 2019;9:7239-50. [PMID: 31695765 DOI: 10.7150/thno.35573] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 8.7] [Reference Citation Analysis]
47 Zhou HQ, Liu MS, Deng TB, Xie PB, Wang W, Shao T, Wu Y, Zhang P. The TGF-β/Smad Pathway Inhibitor SB431542 Enhances The Antitumor Effect Of Radiofrequency Ablation On Bladder Cancer Cells. Onco Targets Ther 2019;12:7809-21. [PMID: 31576139 DOI: 10.2147/OTT.S212596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
48 Yin F, Feng F, Wang L, Wang X, Li Z, Cao Y. SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity. Cell Death Dis 2019;10:672. [PMID: 31511501 DOI: 10.1038/s41419-019-1884-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 55] [Article Influence: 10.0] [Reference Citation Analysis]
49 Wang L, En H, Yang L, Zhang Y, Sun B, Gao J. miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib. Onco Targets Ther 2019;12:6825-38. [PMID: 31686840 DOI: 10.2147/OTT.S215145] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
50 Hou FJ, Guo LX, Zheng KY, Song JN, Wang Q, Zheng YG. Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells. Onco Targets Ther 2019;12:6685-97. [PMID: 31695406 DOI: 10.2147/OTT.S215103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Huo Y, Wang Q, Liu Y, Wang J, Li Q, Li Z, Dong Y, Huang Y, Wang L. A temperature-sensitive phase-change hydrogel of topotecan achieves a long-term sustained antitumor effect on retinoblastoma cells. Onco Targets Ther 2019;12:6069-82. [PMID: 31534347 DOI: 10.2147/OTT.S214024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
52 Zhu L, Liu Z, Dong R, Wang X, Zhang M, Guo X, Yu N, Zeng A. MicroRNA-3662 targets ZEB1 and attenuates the invasion of the highly aggressive melanoma cell line A375. Cancer Manag Res 2019;11:5845-56. [PMID: 31388313 DOI: 10.2147/CMAR.S200540] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
53 Meng D, Lei H, Zheng X, Han Y, Sun R, Zhao D, Liu R. A temperature-sensitive phase-change hydrogel of tamoxifen achieves the long-acting antitumor activation on breast cancer cells. Onco Targets Ther 2019;12:3919-31. [PMID: 31213826 DOI: 10.2147/OTT.S201421] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
54 Chen J, Li N, Wang B, Liu X, Liu J, Chang Q. Upregulation of CBP by PLY can cause permeability of blood‐brain barrier to increase meningitis. J Biochem Mol Toxicol 2019;33. [DOI: 10.1002/jbt.22333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
55 Wei L, Lun Y, Zhou X, He S, Gao L, Liu Y, He Z, Li B, Wang C. Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo. Pharmacol Res 2019;143:73-85. [PMID: 30862605 DOI: 10.1016/j.phrs.2019.03.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
56 Gao X, Chen H, Huang X, Li H, Liu Z, Bo X. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance. Onco Targets Ther 2019;12:1629-40. [PMID: 30881018 DOI: 10.2147/OTT.S196713] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
57 Wang Y, Tang Z. A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells. Onco Targets Ther 2018;11:8529-41. [PMID: 30555243 DOI: 10.2147/OTT.S188209] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
58 Meng D, Meng M, Luo A, Jing X, Wang G, Huang S, Luo M, Shao S, Zhao X, Liu R. Effects of VEGFR1+ hematopoietic progenitor cells on pre-metastatic niche formation and in vivo metastasis of breast cancer cells. J Cancer Res Clin Oncol. 2019;145:411-427. [PMID: 30483898 DOI: 10.1007/s00432-018-2802-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
59 Wang L, Zhao L, Jia X, Jiang L, Song Y, Ye Q, Lyu Z. Aminophenols increase proliferation of thyroid tumor cells by inducing the transcription factor activity of estrogen receptor α. Biomed Pharmacother 2019;109:621-8. [PMID: 30399599 DOI: 10.1016/j.biopha.2018.10.168] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
60 Meng D, Lei M, Han Y, Zhao D, Zhang X, Yang Y, Liu R. MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells. Onco Targets Ther 2018;11:7733-43. [PMID: 30464522 DOI: 10.2147/OTT.S187221] [Cited by in Crossref: 13] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
61 Chen Y, Zeng Q, Liu X, Fu J, Zeng Z, Zhao Z, Liu Z, Bai W, Dong Z, Liu H, Lu X, Zhu Y, Lu Y. LINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cells. Cancer Manag Res 2018;10:4421-38. [PMID: 30349375 DOI: 10.2147/CMAR.S176088] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
62 Li J, Zhao J, Wang H, Li X, Liu A, Qin Q, Li B. MicroRNA-140-3p enhances the sensitivity of hepatocellular carcinoma cells to sorafenib by targeting pregnenolone X receptor. Onco Targets Ther 2018;11:5885-94. [PMID: 30271172 DOI: 10.2147/OTT.S179509] [Cited by in Crossref: 26] [Cited by in F6Publishing: 37] [Article Influence: 6.5] [Reference Citation Analysis]
63 Chen Z, Jiang Z, Zhang W, He B. Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib. Cancer Manag Res 2018;10:3057-67. [PMID: 30214300 DOI: 10.2147/CMAR.S167781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
64 Shao Z, Li Y, Dai W, Jia H, Zhang Y, Jiang Q, Chai Y, Li X, Sun H, Yang R, Cao Y, Feng F, Guo Y. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR. Pharmacol Res 2018;135:188-200. [PMID: 30114438 DOI: 10.1016/j.phrs.2018.08.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 61] [Article Influence: 7.5] [Reference Citation Analysis]
65 Zhang Y, Li D, Jiang Q, Cao S, Sun H, Chai Y, Li X, Ren T, Yang R, Feng F, Li BA, Zhao Q. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis 2018;9:743. [PMID: 29970890 DOI: 10.1038/s41419-018-0804-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 67] [Article Influence: 10.5] [Reference Citation Analysis]
66 Feng F, Jiang Q, Jia H, Sun H, Chai Y, Li X, Rong G, Zhang Y, Li Z. Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis. Pharmacol Res 2018;135:89-101. [PMID: 29959032 DOI: 10.1016/j.phrs.2018.06.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
67 Xie H, Tian S, Yu H, Yang X, Liu J, Wang H, Feng F, Guo Z. A new apatinib microcrystal formulation enhances the effect of radiofrequency ablation treatment on hepatocellular carcinoma. Onco Targets Ther 2018;11:3257-65. [PMID: 29910621 DOI: 10.2147/OTT.S165000] [Cited by in Crossref: 17] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
68 Wu M, Zhao G, Zhuang X, Zhang T, Zhang C, Zhang W, Zhang Z. Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells. Onco Targets Ther 2018;11:2945-54. [PMID: 29849464 DOI: 10.2147/OTT.S165436] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
69 Mackowiak B, Hodge J, Stern S, Wang H. The Roles of Xenobiotic Receptors: Beyond Chemical Disposition. Drug Metab Dispos 2018;46:1361-71. [PMID: 29759961 DOI: 10.1124/dmd.118.081042] [Cited by in Crossref: 34] [Cited by in F6Publishing: 46] [Article Influence: 8.5] [Reference Citation Analysis]
70 Ma Y, Wang C, Zhang Q, Peng X, Feng Y, Meng X. The effects of polysaccharides from Auricularia auricula (Huaier) in adjuvant anti-gastrointestinal cancer therapy: A systematic review and network meta-analysis. Pharmacol Res 2018;132:80-9. [PMID: 29673791 DOI: 10.1016/j.phrs.2018.04.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]